← Leaderboards
Jessie L.-S. Au
Ohio State University
$10,705,345
Attributed
$14,119,005
Total exposure
13
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–17$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$14,119,005 · 13
By mechanism
R01$11,273,979 · 9
R37$1,534,527 · 1
R21$662,813 · 1
R43$647,686 · 2
Top collaborators
- M Guillaume Wientjes19 shared
- Ze Lu3 shared
Most similar at Ohio State University
Same institution · by research overlap
- Todd L Lowary$630,518
- Xuefeng Liu$6,815,737
- Thomas S Lin$2,451,525
Others in their field
Top investigators on “Paclitaxel”
- Philip J Disaia · University Of California Irvine$78,859,922
- Charles A Coltman · Southwest Oncology Group$55,360,646
- Norman Wolmark · Nsabp Foundation, Inc.$52,338,276
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Robert C Park · American College Of Ob And Gyn$16,339,593
- Gerold Bepler · Wayne State University$10,219,123
Research focus
PaclitaxelTumorDoseIn VivoIn VitroChemotherapyMalignant NeoplasmsPharmaceutical PreparationsSuraminResearch Clinical TestingCombined Modality TherapyMolecularNeoplasm /Cancer ChemotherapyBaseComputer SimulationToxic EffectCytotoxicityAnimalsCellsMediatingTreatment ProtocolsMolecular TargetResponseAntineoplastics
Grant awards (48)
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2017 · CA
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2016 · CA
Targeting multiple signaling steps to achieve synergy$378,396
R01 · FY2015 · CA
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2015 · CA
Synergistic chemo-siRNA combination therapy$361,309
R01 · FY2014 · CA
Multiscale computational models for developing combination cancer therapy$337,479
R01 · FY2014 · GM · contact PI
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$302,686
R01 · FY2014 · EB · contact PI
Targeting multiple signaling steps to achieve synergy$1
R01 · FY2014 · CA
Targeting multiple signaling steps to achieve synergy$366,694
R01 · FY2013 · CA
Synergistic chemo-siRNA combination therapy$350,134
R01 · FY2013 · CA
Multiscale computational models for developing combination cancer therapy$325,667
R01 · FY2013 · GM · contact PI
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$294,261
R01 · FY2013 · EB · contact PI
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2012 · CA
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2012 · CA
Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer$344,460
R43 · FY2012 · TR
Multiscale computational models for developing combination cancer therapy$337,479
R01 · FY2012 · GM · contact PI
Telomeres, telomerase and chemotherapy: Bench to bedside$333,500
R01 · FY2012 · CA · contact PI
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$297,956
R01 · FY2012 · EB · contact PI
Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder ca$105,157
R43 · FY2012 · CA
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2011 · CA
Multiscale computational models for developing combination cancer therapy$286,700
R01 · FY2011 · GM · contact PI
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$253,124
R01 · FY2011 · EB · contact PI
Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder ca$198,069
R43 · FY2011 · CA
Telomeres, telomerase and chemotherapy: Bench to bedside$1
R01 · FY2011 · CA · contact PI
Telomeres, telomerase and chemotherapy: Bench to bedside$352,225
R01 · FY2010 · CA · contact PI
Telomeres, telomerase and chemotherapy: Bench to bedside$346,857
R01 · FY2009 · CA · contact PI
Telomeres, telomerase and chemotherapy: Bench to bedside$338,540
R01 · FY2008 · CA · contact PI
Telomeres, telomerase and chemotherapy: Bench to bedside$312,217
R01 · FY2007 · CA · contact PI
Chemoresistance in Renal Cell Cancer$261,855
R01 · FY2006 · CA · contact PI
Chemoresistance in Renal Cell Cancer$269,848
R01 · FY2005 · CA
FGF: A Mechanism of Acquired Multidrug Resistance$245,219
R01 · FY2005 · CA
Chemoresistance in Renal Cell Cancer$282,108
R01 · FY2004 · CA
FGF: A Mechanism of Acquired Multidrug Resistance$245,219
R01 · FY2004 · CA
Chemoresistance in Renal Cell Cancer$328,188
R01 · FY2003 · CA
FGF: A Mechanism of Acquired Multidrug Resistance$245,219
R01 · FY2003 · CA
PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY$110,625
R37 · FY2003 · CA
Chemoresistance in Renal Cell Cancer$382,188
R01 · FY2002 · CA
Suramin to Enchance Paclitaxel and Carboplatin in NSCLC$331,875
R21 · FY2002 · CA
PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY$291,479
R37 · FY2002 · CA
FGF: A Mechanism of Acquired Multidrug Resistance$245,219
R01 · FY2002 · CA
PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY$584,923
R37 · FY2001 · CA
Suramin to Enchance Paclitaxel and Carboplatin in NSCLC$330,938
R21 · FY2001 · CA
CHEMORESISTANCE OF METASTATIC TUMORS$141,940
R01 · FY2001 · CA
TELOMERES, TELOMERASE, AND CHEMOTHERAPY$99,310
R01 · FY2001 · CA
PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY$547,500
R37 · FY2000 · CA
TELOMERES, TELOMERASE, AND CHEMOTHERAPY$297,932
R01 · FY2000 · CA
CHEMORESISTANCE OF METASTATIC TUMORS$244,642
R01 · FY2000 · CA
PHARMACOLOGY-BASED EFFICACY TRIAL OF INTRAVESICAL MMC$122,117
R01 · FY2000 · CA